UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13D/A

(Amendment No. 4)*

 

 

Under the Securities Exchange Act of 1934

Aeolus Pharmaceuticals, Inc.

(Name of Issuer)

 

COMMON STOCK

(Title of Class of Securities)

 

00765G109

(CUSIP Number)

 

EFFICACY CAPITAL LTD.

 

 

 

with a copy to:

 

 

Mintz Levin Cohn Ferris Glovsky and Popeo PC

Mark Lappe, Managing Partner

 

Jeremy D. Glaser, Esq.

11099 N. Torrey Pines Road, Suite 130

 

3580 Carmel Mountain Road, Suite 300

San Diego, CA 92137

 

San Diego, CA 92130

Phone: (858) 568-7562

 

Phone: (858) 314-1500

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

March 19, 2012

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 


 

CUSIP No.   00765G109

 

 

1.

Names of Reporting Persons
EFFICACY BIOTECH FUND L.P.

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
WC

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
Not applicable

 

 

6.

Citizenship or Place of Organization
DELAWARE, USA

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power
3,724,125 shares*

 

9.

Sole Dispositive Power
0

 

10.

Shared Dispositive Power
3,724,125 shares*

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,724,125 shares*

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
Not applicable

 

 

13.

Percent of Class Represented by Amount in Row (11)
6.1%

 

 

14.

Type of Reporting Person (See Instructions)
PN

 

* See Item 5.

 

2


 

CUSIP No.   00765G109

 

 

1.

Names of Reporting Persons
EFFICACY BIOTECH FUND LIMITED

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
WC

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
Not applicable

 

 

6.

Citizenship or Place of Organization
BERMUDA

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power
3,724,125shares*

 

9.

Sole Dispositive Power
0

 

10.

Shared Dispositive Power
3,724,125 shares*

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,724,125 shares*

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
Not applicable

 

 

13.

Percent of Class Represented by Amount in Row (11)
6.1%

 

 

14.

Type of Reporting Person (See Instructions)
OO

 

* See Item 5.

 

3


 

CUSIP No.   00765G109

 

 

1.

Names of Reporting Persons
EFFICACY BIOTECH MASTER FUND LTD.

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
WC

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
Not applicable

 

 

6.

Citizenship or Place of Organization
BERMUDA

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power
3,724,125 shares*

 

9.

Sole Dispositive Power
0

 

10.

Shared Dispositive Power
3,724,125 shares*

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,724,125 shares*

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
Not applicable

 

 

13.

Percent of Class Represented by Amount in Row (11)
6.1%

 

 

14.

Type of Reporting Person (See Instructions)
OO

 

* See Item 5.

 

4


 

CUSIP No.   00765G109

 

 

1.

Names of Reporting Persons
EFFICACY CAPITAL LTD.

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
WC

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
Not applicable

 

 

6.

Citizenship or Place of Organization
BERMUDA

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power
3,724,125 shares*

 

9.

Sole Dispositive Power
0

 

10.

Shared Dispositive Power
3,724,125shares*

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,724,125 shares*

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
Not applicable

 

 

13.

Percent of Class Represented by Amount in Row (11)
6.1%

 

 

14.

Type of Reporting Person (See Instructions)
OO

 

* See Item 5.

 

5


 

CUSIP No.   00765G109

 

 

1.

Names of Reporting Persons
MARK LAPPE

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
OO

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
Not applicable

 

 

6.

Citizenship or Place of Organization
USA

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
3,724,125 shares*

 

8.

Shared Voting Power
0

 

9.

Sole Dispositive Power
3,724,125 shares*

 

10.

Shared Dispositive Power
0

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,724,125 shares*

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
Not applicable

 

 

13.

Percent of Class Represented by Amount in Row (11)
6.1%

 

 

14.

Type of Reporting Person (See Instructions)
IN

 

6


 

Item 1.

Security and Issuer

 

(a)                                 Name of Issuer:  Aeolus Pharmaceuticals, Inc

 

(b)                                 Address of Issuer's Principal Executive Offices:

 

26361 Crown Valley Parkway, Suite 150

Mission Viejo, CA  92691

 

(c)                                  Title of Class of Securities:  Common Stock

 

Item 2.

Identity and Background

 

(a)                                 Name of Person Filing:

 

See Item 1 of each cover page.

 

Pursuant to Rule 13d-1(a) of General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the “Act”), the undersigned hereby file this Schedule 13D Statement (this “Schedule 13D”) on behalf of (i) Mark Lappe, (ii) Efficacy Capital Ltd., a Bermuda limited liability company (“Efficacy Capital”), (iii) Efficacy Biotech Fund, L.P., a Delaware limited partnership (“EBF”), (iv) Efficacy Biotech Fund Limited, a Bermuda Exempted Mutual Fund Company (“EBFL”), and (v) Efficacy Biotech Master Fund Ltd., a Bermuda Exempted Mutual Fund Company (“EBMFL”) (collectively, the “Reporting Persons”).

 

(b)                                 Address of Principal Business Office or, if none, Residence:

 

11099 N. Torrey Pines Road, Suite 130

La Jolla, CA  92037

 

(c)                                  Mark Lappe is the Managing Partner of Efficacy Capital Ltd., the Investment Manager for the Reporting Persons.

 

(d)                                 None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e)                                  The Reporting Persons have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and have not been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

 

(f)                                   Citizenship:

 

See Item 6 of each cover page.

 

Item 3.

Source and Amount of Funds or Other Consideration

 

All of the funds used to purchase the Common Stock were from the working capital of one or more of the Reporting Persons except for the June 30, 2011 transaction.  This transaction was a recordkeeping adjustment.

 

7


 

Item 4.

Purpose of Transaction

 

The acquisitions described in Item 5 were made for investment purposes.  The Reporting Persons do not presently have any plans or proposals which relate to or would result in any of the transactions described in Item 4 of Schedule 13D.

 

Item 5.

Interest in Securities of the Issuer

 

(a)                                 The Reporting Persons collectively own shares or rights to purchase up to 3,724,125 shares of the Issuer’s Common Stock comprising 6.1% of the Issuer’s outstanding Common Stock.

 

(b)                                 No material change.

 

(c)                                  The following transactions were effected since the most recent Schedule D filing:

 

Reporting Person

 

Date of Transaction

 

Amount of
Securities Involved

 

Price per Share

 

Where and How
Effected

 

Efficacy Capital Ltd.

 

06/30/2011

 

68,494.00

 

$

0.30

 

Recordkeeping Correction

 

Efficacy Capital Ltd.

 

07/05/2011

 

(10,000.00

)

$

0.47

 

Open Market

 

Efficacy Capital Ltd.

 

07/07/2011

 

(12,000.00

)

$

0.47

 

Open Market

 

Efficacy Capital Ltd

 

07/11/2011

 

(20,000.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

07/12/2011

 

(14,100.00

)

$

0.43

 

Open Market

 

Efficacy Capital Ltd.

 

07/13/2011

 

(500.00

)

$

0.41

 

Open Market

 

Efficacy Capital Ltd.

 

07/14/2011

 

(5,000.00

)

$

0.38

 

Open Market

 

Efficacy Capital Ltd.

 

07/15/2011

 

(10,500.00

)

$

0.38

 

Open Market

 

Efficacy Capital Ltd.

 

08/05/2011

 

(2,000.00

)

$

0.44

 

Open Market

 

Efficacy Capital Ltd.

 

08/08/2011

 

(1,000.00

)

$

0.43

 

Open Market

 

Efficacy Capital Ltd.

 

08/10/2011

 

(100.00

)

$

0.24

 

Open Market

 

Efficacy Capital Ltd.

 

08/11/2011

 

(2,000.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

08/15/2011

 

(3,000.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

08/24/2011

 

(3,200.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

08/25/2011

 

(5,400.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

08/30/2011

 

(20,000.00

)

$

0.42

 

Open Market

 

Efficacy Capital Ltd.

 

08/31/2011

 

(5,000.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

09/01/2011

 

(2,500.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

09/08/2011

 

(4,400.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

09/21/2011

 

(7,000.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

09/22/2011

 

(5,000.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

09/23/2011

 

(850.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

10/10/2011

 

(10,000.00

)

$

0.48

 

Open Market

 

Efficacy Capital Ltd.

 

01/23/2012

 

(1,775.00

)

$

0.35

 

Open Market

 

Efficacy Capital Ltd.

 

01/25/2012

 

(10,000.00

)

$

0.35

 

Open Market

 

Efficacy Capital Ltd.

 

01/26/2012

 

(1,250.00

)

$

0.35

 

Open Market

 

Efficacy Capital Ltd.

 

01/27/2012

 

(35,000.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

01/30/2012

 

(10,000.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

01/31/2012

 

(4,700.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

02/02/2012

 

(100,000.00

)

$

0.31

 

Open Market

 

Efficacy Capital Ltd.

 

02/07/2012

 

(3,448.00

)

$

0.30

 

Open Market

 

Efficacy Capital Ltd.

 

02/08/2012

 

(20,000.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

02/10/2012

 

(10,000.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

02/13/2012

 

(1,200.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

02/14/2012

 

(7,700.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

02/15/2012

 

(22,700.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

02/16/2012

 

(14,682.00

)

$

0.32

 

Open Market

 

 

8


 

Efficacy Capital Ltd.

 

02/17/2012

 

(20,000.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

02/21/2012

 

(950.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

02/23/2012

 

(10,600.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

02/27/2012

 

(20,000.00

)

$

0.31

 

Open Market

 

Efficacy Capital Ltd.

 

02/28/2012

 

(6,250.00

)

$

0.31

 

Open Market

 

Efficacy Capital Ltd.

 

02/29/2012

 

(5,500.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

03/01/2012

 

(5,000.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/05/2012

 

(14,800.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/06/2012

 

(420.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/07/2012

 

(30,000.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/06/2012

 

(420.00

)

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/06/2012

 

420.00

 

$

0.34

 

Open Market

 

Efficacy Capital Ltd.

 

03/08/2012

 

(10,432.00

)

$

0.35

 

Open Market

 

Efficacy Capital Ltd.

 

03/13/2012

 

(2,350.00

)

$

0.36

 

Open Market

 

Efficacy Capital Ltd.

 

03/14/2012

 

(8,000.00

)

$

0.32

 

Open Market

 

Efficacy Capital Ltd.

 

03/16/2012

 

(100,000.00

)

$

0.33

 

Open Market

 

Efficacy Capital Ltd.

 

03/19/2012

 

(5,000.00

)

$

0.32

 

Open Market

 

 

 

(d)                                 No person other than the Reporting Persons has rights with respect to the economic or voting interests associated with the Shares.

 

(e)                                  Not applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

No material change.

 

Item 7.

Material to be Filed as Exhibits

 

Exhibit A                                             JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

 

9


 

Signatures

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

April 10, 2012

 

Date

 

 

 

/s/ Mark Lappe

 

Mark Lappe

 

 

 

 

 

Efficacy Capital Ltd.,

 

a Bermuda limited liability company

 

 

 

 

 

/s/ Mark Lappe

 

By: Mark Lappe

 

 

Its: Managing Partner

 

 

 

 

 

 

 

 

Efficacy Biotech Fund, L.P.,

 

a Delaware limited partnership

 

 

 

 

 

 

 

By:  Efficacy Capital Ltd.

 

 

Its:  General Partner

 

 

 

 

 

 

 

 

/s/ Mark Lappe

 

 

By: Mark Lappe

 

 

 

Its: Managing Partner

 

 

 

 

 

 

Efficacy Biotech Fund Limited,

 

a Bermuda Exempted Mutual Fund Company

 

 

 

 

 

 

By:  Efficacy Capital Ltd.

 

 

Its:  Manager

 

 

 

 

 

 

 

 

/s/ Mark Lappe

 

 

By: Mark Lappe

 

 

Its: Managing Partner

 

 

 

 

 

Efficacy Biotech Master Fund Ltd.,

 

a Bermuda Exempted Mutual Fund Company

 

 

 

 

 

By:  Efficacy Capital Ltd.

 

 

Its:  Manager

 

 

 

 

 

 

/s/ Mark Lappe

 

 

By: Mark Lappe

 

 

Its: Managing Partner

 

10


 

Exhibit A

 

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

 

Date: April 10, 2012

 

 

/s/ Mark Lappe

 

Mark Lappe

 

 

 

 

 

Efficacy Capital, Ltd,

 

a Bermuda limited liability company

 

 

 

 

 

/s/ Mark Lappe

 

By: Mark Lappe

 

Its: Managing Partner

 

 

 

 

 

Efficacy Biotech Fund, L.P.,

 

a Delaware limited partnership

 

 

 

By:  Efficacy Capital Ltd.

 

Its:  General Partner

 

 

 

 

 

/s/ Mark Lappe

 

By: Mark Lappe

 

 

 

 

 

Efficacy Biotech Fund Limited,

 

a Bermuda Exempted Mutual Fund Company

 

 

 

By:  Efficacy Capital Ltd.

 

Its:  Manager

 

 

 

 

 

/s/ Mark Lappe

 

By: Mark Lappe

 

Its: Managing Partner

 

11


 

 

Efficacy Biotech Master Fund Ltd.,

 

a Bermuda Exempted Mutual Fund Company

 

 

 

 

 

By:  Efficacy Capital Ltd.

 

Its:  Manager

 

 

 

 

 

/s/ Mark Lappe

 

By: Mark Lappe

 

Its: Managing Partner

 

12